The tweet was deleted by the author.
But we saved everything 🙂.
Arcturus Therapeutics presented a new research poster at the Society for Inherited Metabolic Disorders (SIMD) 2026 Annual Meeting.
The company highlighted its ongoing efforts in developing mRNA-based treatments for urea cycle disorders (UCD) and ornithine transcarbamylase (OTC) deficiency. Attendees who missed the live presentation are encouraged to review the poster online. This development underscores Arcturus Therapeutics' continued commitment to advancing innovative therapies for rare genetic metabolic conditions.
Arcturus Therapeutics previously announced it would present research on mRNA-based therapies for OTC deficiency at the SIMD 2026 Annual Meeting. The company has also reported that 10 percent of cystic fibrosis patients remain untreated by current therapies. These efforts highlight Arcturus's ongoing focus on rare genetic and metabolic conditions.